Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It contains specific transaction data for a single executive:
- Instrument: Ordinary Shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares via dividend re-investment.
- Transaction Date: July 14, 2016.
- Price: £16.6781 per share.
- Volume: 417.504 shares.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely discloses a routine share acquisition by an executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The transaction was executed following the dividend payment to shareholders on July 14, 2016.
Investor Verification Points
- Verify the identity of the PDMR: Mr. P C Thomson, SVP, Communications & Government Affairs.
- Confirm the transaction was an automatic dividend re-investment rather than an open market purchase.
- Note that this filing does not reflect the company's overall financial performance for the period.